Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [31] Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2-Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population
    Zhang, Yusi
    Chen, Wenlin
    Chen, Shuanglong
    Yang, Qingmo
    Ouyang, Zhong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [32] Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2-metastatic breast cancer: A Flatiron Health database analysis
    Layman, Rachel M.
    Liu, Xianchen
    Li, Benjamin
    Mcroy, Lynn
    Brufsky, Adam
    BREAST, 2025, 81
  • [33] Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2-breast cancer
    Li, Siwei
    Zhang, Xianyu
    Pang, Da
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [34] Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 32
  • [35] Survey of Health Care Providers on Social Determinants of Health and Treatment Decision-Making for Patients With HR+/HER2− Metastatic Breast Cancer
    Monique Gary
    Editha Krueger
    Molly Kisiel
    Kimberly Demirhan
    Alexandra Guarin Barajas
    Joanne C. Ryan
    Oncology and Therapy, 2025, 13 (2) : 429 - 446
  • [36] Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2-Advanced Breast Cancer: A Nationwide Real-World Experience
    Boer, Katalin
    Rubovszky, Gabor
    Rokszin, Gyorgy
    Abonyi-Toth, Zsolt
    Foldesi, Csenge
    Dank, Magdolna
    ONCOTARGETS AND THERAPY, 2021, 14 : 3971 - 3981
  • [37] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
    Dalal, Anand A.
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (09) : 1356 - 1367
  • [38] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024, 20 (29) : 2165 - 2177
  • [39] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [40] Outcomes of male patients with HR+/HER2-advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Blum, Joanne L.
    Dicristo, Caroline
    Gordon, David
    Karuturi, Meghan S.
    Oubre, David
    Jepsen, Erin
    Cuevas, Juan
    Lakhanpal, Shailendra
    Montelongo, Monica Z.
    Zhang, Zhe
    Cappelleri, Joseph C.
    Wang, Yao
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 463 - 475
12345